Ventyx Biosciences (VTYX) Projected to Post Earnings on Thursday

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.13. On average, analysts expect Ventyx Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ventyx Biosciences Trading Down 6.9 %

VTYX stock traded down $0.10 during mid-day trading on Tuesday, hitting $1.29. 195,412 shares of the company were exchanged, compared to its average volume of 1,271,222. The stock has a market capitalization of $91.44 million, a PE ratio of -0.54 and a beta of 0.73. The business has a 50 day simple moving average of $1.24 and a 200-day simple moving average of $1.82. Ventyx Biosciences has a 1-year low of $0.78 and a 1-year high of $5.66.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "neutral" rating on shares of Ventyx Biosciences in a research note on Tuesday, January 14th.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.